Haemonetics 관리

관리 기준 확인 3/4

Haemonetics CEO는 Chris Simon, May2016 에 임명되었습니다 의 임기는 8.5 년입니다. 총 연간 보상은 $ 11.55M, 9.4% 로 구성됩니다. 9.4% 급여 및 90.6% 보너스(회사 주식 및 옵션 포함). 는 $ 23.47M 가치에 해당하는 회사 주식의 0.55% 직접 소유합니다. 23.47M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 7 년입니다.

주요 정보

Chris Simon

최고 경영자

US$11.5m

총 보상

CEO 급여 비율	9.4%
CEO 임기	8.5yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

Recent updates

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03

CEO 보상 분석

Chris Simon 의 보수는 Haemonetics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 28 2024	n/a	n/a	US$124m
Jun 29 2024	n/a	n/a	US$115m
Mar 30 2024	US$12m	US$1m	US$118m
Dec 30 2023	n/a	n/a	US$127m
Sep 30 2023	n/a	n/a	US$128m
Jul 01 2023	n/a	n/a	US$137m
Apr 01 2023	US$11m	US$1m	US$115m
Dec 31 2022	n/a	n/a	US$96m
Oct 01 2022	n/a	n/a	US$86m
Jul 02 2022	n/a	n/a	US$68m
Apr 02 2022	US$9m	US$945k	US$43m
Jan 01 2022	n/a	n/a	US$23m
Oct 02 2021	n/a	n/a	US$31m
Jul 03 2021	n/a	n/a	US$64m
Apr 03 2021	US$9m	US$963k	US$79m
Dec 26 2020	n/a	n/a	US$108m
Sep 26 2020	n/a	n/a	US$106m
Jun 27 2020	n/a	n/a	US$96m
Mar 28 2020	US$9m	US$937k	US$77m
Dec 28 2019	n/a	n/a	US$80m
Sep 28 2019	n/a	n/a	US$68m
Jun 29 2019	n/a	n/a	US$49m
Mar 30 2019	US$9m	US$894k	US$55m
Dec 29 2018	n/a	n/a	US$46m
Sep 29 2018	n/a	n/a	US$21m
Jun 30 2018	n/a	n/a	US$23m
Mar 31 2018	US$8m	US$858k	US$46m

보상 대 시장: Chris 의 총 보상 ($USD 11.55M )은 US 시장( $USD 6.60M ).

보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chris Simon (60 yo)

8.5yrs

테뉴어

US$11,545,113

보상

Mr. Christopher A. Simon, also known as Chris, has been the Chief Executive Officer and President of Haemonetics Corporation since May 16, 2016 and has been its Director since May 2016. He joined Haemoneti...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Simon	CEO, President & Director	8.5yrs	US$11.55m	0.55% $ 23.5m
James D'Arecca	CFO, Executive VP & Financial Officer	2.6yrs	US$3.15m	0.0095% $ 404.7k
Michelle Basil	Executive VP	7.7yrs	US$3.07m	0.039% $ 1.7m
Josep Llorens	Executive Vice President of Global Manufacturing & Supply Chain	6.3yrs	US$2.43m	0.039% $ 1.7m
Farris Maunsell	VP, Chief Accounting Officer & Principal Accounting Officer	2.1yrs	데이터 없음	0.00027% $ 11.5k
Olga Guyette	Senior Director of Investor Relations	5.1yrs	데이터 없음	데이터 없음
Rajeev Varma	Senior Vice President of Strategy & Corporate Development	1.6yrs	데이터 없음	데이터 없음
Laurie Miller	Senior VP & Chief Human Resources Officer	3.3yrs	데이터 없음	0.023% $ 997.6k
Jan Hartmann	Senior VP & Chief Medical Officer	1.6yrs	데이터 없음	데이터 없음
Stewart Strong	President of Global Hospital	5.2yrs	US$2.48m	0.036% $ 1.5m
Kerri DiPietro	Senior Vice President of Global Quality Assurance	3.3yrs	데이터 없음	데이터 없음
Roy Galvin	President of Global Plasma & Blood Center	2.1yrs	데이터 없음	0.0036% $ 154.0k

3.3yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: HAE 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Simon	CEO, President & Director	8.2yrs	US$11.55m	0.55% $ 23.5m
Robert Abernathy	Independent Director	7.1yrs	US$295.73k	0.036% $ 1.5m
Michael Coyle	Independent Director	4.6yrs	US$283.73k	0.016% $ 702.0k
Ellen Zane	Independent Chairman	6.8yrs	US$449.98k	0.024% $ 1.0m
Claire Pomeroy	Independent Director	5.6yrs	US$269.95k	0.019% $ 827.8k
Mark Kroll	Independent Director	18.8yrs	US$280.73k	0.032% $ 1.4m
Charles Dockendorff	Independent Director	10.3yrs	US$292.95k	0.036% $ 1.5m
Lloyd Johnson	Independent Director	3.3yrs	US$272.95k	0.012% $ 493.0k
James Grotta	Member of Scientific Advisory Council	no data	데이터 없음	데이터 없음
Bryan Cotton	Member of Scientific Advisory Council	no data	데이터 없음	데이터 없음
Melissa Cushing	Member of Scientific Advisory Council	no data	데이터 없음	데이터 없음
Steven Frank	Member of Scientific Advisory Council	no data	데이터 없음	데이터 없음

7.0yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: HAE 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Haemonetics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insufficient new directors

President of Global Hospital notifies of intention to sell stock

CEO, President & Director exercised options and sold US$3.3m worth of stock

Haemonetics Corporation, Annual General Meeting, Jul 25, 2024

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Recent updates

Second quarter 2025 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 22%

Haemonetics Corporation to Report Q2, 2025 Results on Nov 07, 2024

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Insufficient new directors

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

First quarter 2025 earnings: EPS exceeds analyst expectations

President of Global Hospital notifies of intention to sell stock

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Corporation to Report Q1, 2025 Results on Aug 08, 2024

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Haemonetics Corporation Launches Limited Market Release of its New VASCADE MVP XL Mid-Bore Venous Closure Device

CEO, President & Director exercised options and sold US$3.3m worth of stock

Haemonetics Corporation, Annual General Meeting, Jul 25, 2024

Executive VP notifies of intention to sell stock

New minor risk - Earnings quality

New minor risk - Earnings quality

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2025

Full year 2024 earnings released: EPS: US$2.32 (vs US$2.27 in FY 2023)

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation to Report Q4, 2024 Results on May 09, 2024

Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge

Haemonetics Corporation (NYSE:HAE) completed the acquisition of Advanced Cooling Therapy, Inc.

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Haemonetics Corporation (NYSE:HAE) has entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc. for $160 million.

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024

Haemonetics Corporation to Report Q3, 2024 Results on Feb 08, 2024

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics: Solid Performance Of This Blood Play

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Haemonetics Corporation Revises Revenue Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

Haemonetics Corporation to Report Q2, 2024 Results on Nov 02, 2023

Independent Director notifies of intention to sell stock

Price target increased by 8.3% to US$109

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Haemonetics Corporation Elects Diane M. Bryant to Its Board of Directors

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Insider notifies of intention to sell stock

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics Corporation to Report Q1, 2024 Results on Aug 08, 2023

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

CEO, President & Director exercised options and sold US$6.6m worth of stock

Haemonetics Corporation Receives FDA Clearance for Enhancements to NexSys PCS(R) Plasma Collection System

Haemonetics Corporation, Annual General Meeting, Aug 04, 2023

Executive VP & CTO recently sold US$192k worth of stock

Consensus EPS estimates increase by 25%

Haemonetics Corporation Provides Revenue Guidance for the Fiscal Year 2024

Full year 2023 earnings released: EPS: US$2.27 (vs US$0.85 in FY 2022)

Insufficient new directors

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Haemonetics Corporation Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Insider notifies of intention to sell stock

Investor sentiment improved over the past week